300702.SZ Overview

Company Profile

Zhejiang Tianyu Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical intermediates and APIs in China and internationally. The company offers pharmaceutical intermediates and APIs of anti-hypertensive, anti-allergic, anticancer, anti-fungal, anti-epileptic, anti-asthmatic, hypoglycemic, hypolipidemic, and anticoagulant series. It also provides fine chemicals and CDMO services. The company was founded in 1993 and is headquartered in Taizhou, China.

Related stocks

000650.SZ

000650.SZ • China

RENHE PHARMACY CO LTD

5.29 CNY

1.11B USD 1Y -12.9%

301263.SZ

301263.SZ • China

19.14 CNY

1.22B USD 1Y -31.8%

600195.SS

600195.SS • China

CHINA ANIMAL HUSBANDRY INDUSTRY

6.73 CNY

1.03B USD 1Y -6%

600129.SS

600129.SS • China

CHONGQING TAIJI IND

13.97 CNY

1.15B USD 1Y -36.3%

002349.SZ

002349.SZ • China

9.24 CNY

1.15B USD 1Y +28.3%

600557.SS

600557.SS • China

JIANGSU KANION PHARMACEUTICAL C

12.4 CNY

1.05B USD 1Y -18.4%

600789.SS

600789.SS • China

SHANDONG LUKANG PHARMACEUTICAL

8.28 CNY

1.29B USD 1Y -15.3%

002275.SZ

002275.SZ • China

12.35 CNY

1.09B USD 1Y -16%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile

5 Metrics

Country

Region

Sector

Industry

Drug Manufacturers - Specialty & Generic

Website

https://www.tianyupharm.com

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High

5Y Volatility

45.3% p.a.

Max Drawdown (5Y)

-75.9%

Sharpe Ratio (5Y)

-0.35

Beta Factor

0.32

Size Class

Mid Cap

Notes & Warnings

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).

Exemplary balance sheet strength: Very solid ratio of equity to debt.

🔴 High valuation risk: Avg P/E of 79.2 (Elevated multiple compression risk)

🔴 Low analyst coverage – higher uncertainty in growth estimates & projections

Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (45.3% p.a.).

Historical Stress Test: Maximum peak-to-trough drawdown of -80.6% in the extended horizon.